Does the media refer more to TGTX or AUPH?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 2 mentions for TG Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat TG Therapeutics' score of 1.16 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUPH or APGE?

In the previous week, Apogee Therapeutics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 6 mentions for Apogee Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Apogee Therapeutics' score of 0.54 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUPH or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Vaxcyte's score of 0.04 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AUPH or QGEN?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Qiagen. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 2 mentions for Qiagen. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Qiagen's score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IMVT or AUPH?

In the previous week, Immunovant had 10 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 13 mentions for Immunovant and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Immunovant's score of -0.29 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aurinia Pharmaceuticals (AUPH) Competitors

$15.80 -1.17 (-6.89%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$15.85 +0.05 (+0.30%)

As of 05:38 AM Eastern

Compare

AUPH vs. TGTX, APGE, PCVX, QGEN, and IMVT

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? MarketBeat compares Aurinia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aurinia Pharmaceuticals include TG Therapeutics (TGTX), Apogee Therapeutics (APGE), Vaxcyte (PCVX), Qiagen (QGEN), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

TG Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 2 mentions for TG Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat TG Therapeutics' score of 1.16 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.29	$447.18M	$2.86	18.71
Aurinia Pharmaceuticals	$298.30M	6.81	$287.20M	$2.17	7.28

Aurinia Pharmaceuticals has a net margin of 99.97% compared to TG Therapeutics' net margin of 65.95%. TG Therapeutics' return on equity of 88.73% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

TG Therapeutics presently has a consensus target price of $58.60, indicating a potential upside of 9.49%. Aurinia Pharmaceuticals has a consensus target price of $17.25, indicating a potential upside of 9.18%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

TG Therapeutics beats Aurinia Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Aurinia Pharmaceuticals currently has a consensus target price of $17.25, indicating a potential upside of 9.18%. Apogee Therapeutics has a consensus target price of $121.25, indicating a potential downside of 8.67%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Aurinia Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Apogee Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Apogee Therapeutics	N/A	-32.64%	-31.25%

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aurinia Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$298.30M	6.81	$287.20M	$2.17	7.28
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 6 mentions for Apogee Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Apogee Therapeutics' score of 0.54 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Apogee Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Vaxcyte's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Vaxcyte	N/A	-32.51%	-29.51%

Aurinia Pharmaceuticals presently has a consensus price target of $17.25, indicating a potential upside of 9.18%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 53.35%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Vaxcyte had 4 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Vaxcyte's score of 0.04 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$298.30M	6.81	$287.20M	$2.17	7.28
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

Aurinia Pharmaceuticals beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Qiagen?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Qiagen's net margin of 19.16%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$298.30M	6.81	$287.20M	$2.17	7.28
Qiagen	$2.09B	3.87	$424.88M	$1.91	20.54

Aurinia Pharmaceuticals currently has a consensus price target of $17.25, suggesting a potential upside of 9.18%. Qiagen has a consensus price target of $43.15, suggesting a potential upside of 9.97%. Given Qiagen's higher possible upside, analysts clearly believe Qiagen is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Qiagen. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 2 mentions for Qiagen. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Qiagen's score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aurinia Pharmaceuticals beats Qiagen on 10 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Immunovant had 10 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 13 mentions for Immunovant and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Immunovant's score of -0.29 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant currently has a consensus target price of $39.70, suggesting a potential upside of 4.09%. Aurinia Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 9.18%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Immunovant's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Aurinia Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Aurinia Pharmaceuticals	$298.30M	6.81	$287.20M	$2.17	7.28

Summary

Aurinia Pharmaceuticals beats Immunovant on 13 of the 16 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.18B	$3.06B	$6.79B	$12.59B
Dividend Yield	N/A	2.01%	2.66%	6.14%
P/E Ratio	7.28	19.53	27.43	25.27
Price / Sales	6.81	342.73	531.82	99.38
Price / Cash	16.75	57.40	47.99	59.26
Price / Book	3.58	4.26	11.06	6.62
Net Income	$287.20M	$64.45M	$3.57B	$336.83M
7 Day Performance	-9.97%	4.28%	2.93%	3.25%
1 Month Performance	2.66%	4.75%	3.74%	0.92%
1 Year Performance	110.95%	29.17%	34.44%	27.62%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	2.7653 of 5 stars	$15.80 -6.9%	$17.25 +9.2%	+111.2%	$2.18B	$298.30M	7.28	300	Positive News Analyst Upgrade
TGTX TG Therapeutics	3.3515 of 5 stars	$55.72 -0.2%	$58.60 +5.2%	+51.2%	$8.55B	$616.29M	19.48	290	Positive News
APGE Apogee Therapeutics	1.3985 of 5 stars	$132.61 +0.0%	$121.25 -8.6%	+200.0%	$8.21B	N/A	N/A	91
PCVX Vaxcyte	2.2147 of 5 stars	$57.72 +2.1%	$86.00 +49.0%	+70.2%	$8.16B	N/A	N/A	160	Options Volume
QGEN Qiagen	3.4631 of 5 stars	$39.73 +0.8%	$43.15 +8.6%	-22.7%	$8.12B	$2.09B	20.75	5,654

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. TGTX, APGE, PCVX, QGEN, and IMVT

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Summary

How does Aurinia Pharmaceuticals compare to Qiagen?

Summary

How does Aurinia Pharmaceuticals compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. TGTX, APGE, PCVX, QGEN, and IMVT

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Do insiders & institutionals have more ownership in TGTX or AUPH?

Which has more risk and volatility, TGTX or AUPH?

Does the media refer more to TGTX or AUPH?

Which has higher earnings & valuation, TGTX or AUPH?

Is TGTX or AUPH more profitable?

Do analysts recommend TGTX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Do analysts recommend AUPH or APGE?

Is AUPH or APGE more profitable?

Do insiders and institutionals have more ownership in AUPH or APGE?

Which has better earnings & valuation, AUPH or APGE?

Does the media favor AUPH or APGE?

Which has more volatility and risk, AUPH or APGE?

Summary

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Do insiders & institutionals believe in AUPH or PCVX?

Is AUPH or PCVX more profitable?

Do analysts rate AUPH or PCVX?

Does the media prefer AUPH or PCVX?

Which has more volatility and risk, AUPH or PCVX?

Which has higher valuation and earnings, AUPH or PCVX?

Summary

How does Aurinia Pharmaceuticals compare to Qiagen?

Do insiders & institutionals believe in AUPH or QGEN?

Which has more risk and volatility, AUPH or QGEN?

Is AUPH or QGEN more profitable?

Which has higher earnings & valuation, AUPH or QGEN?

Do analysts rate AUPH or QGEN?

Does the media refer more to AUPH or QGEN?

Summary

How does Aurinia Pharmaceuticals compare to Immunovant?

Does the media refer more to IMVT or AUPH?

Do analysts prefer IMVT or AUPH?

Do institutionals & insiders hold more shares of IMVT or AUPH?

Which has more volatility and risk, IMVT or AUPH?

Is IMVT or AUPH more profitable?

Which has stronger earnings & valuation, IMVT or AUPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools